NasdaqGS:QDEL

Stock Analysis Report

Executive Summary

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal diseases, and toxicology.

Snowflake

Fundamentals

Solid track record with reasonable growth potential.


Similar Companies

Share Price & News

How has Quidel's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.4%

QDEL

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-1.0%

QDEL

9.9%

US Medical Equipment

0.7%

US Market

QDEL underperformed the Medical Equipment industry which returned 9.9% over the past year.

QDEL underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

QDELIndustryMarket
7 Day-4.4%1.1%-0.6%
30 Day5.6%1.3%2.9%
90 Day8.3%3.0%1.3%
1 Year-1.0%-1.0%10.8%9.9%2.9%0.7%
3 Year182.7%182.7%70.1%64.9%44.6%35.2%
5 Year142.0%142.0%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Quidel's share price compared to the market and industry in the last 5 years?


Simply Wall St News

3 weeks ago | Simply Wall St

Is Quidel Corporation's (NASDAQ:QDEL) ROE Of 14% Impressive?

Valuation

Is Quidel undervalued based on future cash flows and its price relative to the stock market?

36.69x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Quidel's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Quidel's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Quidel is good value based on earnings compared to the US Medical Equipment industry average.

Quidel is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Quidel is poor value based on expected growth next year.


Price Based on Value of Assets

Quidel is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Quidel expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

21.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Quidel's revenue is expected to grow by 4.8% yearly, however this is not considered high growth (20% yearly).

Quidel's earnings are expected to grow significantly at over 20% yearly.

Quidel's revenue growth is positive but not above the United States of America market average.

Quidel's earnings growth is expected to exceed the United States of America market average.

Quidel's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Quidel is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Quidel performed over the past 5 years?

74.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Quidel has delivered over 20% year on year earnings growth in the past 5 years.

Quidel's 1-year earnings growth exceeds its 5-year average (242.5% vs 74.9%)

Quidel's earnings growth has exceeded the US Medical Equipment industry average in the past year (242.5% vs 28.2%).


Return on Equity

Quidel has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Quidel used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Quidel has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Quidel's financial position?


Financial Position Analysis

Quidel is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Quidel's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Quidel's level of debt (6%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 6% today).

Debt is well covered by operating cash flow (479.9%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 5x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 5.1x debt.


Next Steps

Dividend

What is Quidel's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Quidel's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Quidel's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Quidel has not reported any payouts.

Unable to verify if Quidel's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Quidel has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Quidel's salary, the management and board of directors tenure and is there insider trading?

5.3yrs

Average management tenure


CEO

Doug Bryant (61yo)

10.5yrs

Tenure

US$3,421,307

Compensation

Mr. Douglas C. Bryant, also known as Doug, has been the Chief Executive Officer and President of Quidel Corp. since March 1, 2009. Mr. Bryant served as the Chief Operating Officer and Executive Vice Presid ...


CEO Compensation Analysis

Doug's remuneration is lower than average for companies of similar size in United States of America.

Doug's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.3yrs

Average Tenure

56yo

Average Age

The average tenure for the Quidel management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.1yrs

Average Tenure

65yo

Average Age

The tenure for the Quidel board of directors is about average.


Insider Trading

Quidel individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$305,64017 Sep 19
Karen Gibson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Information Systems & Business Transformation
Shares4,527
Max PriceUS$67.52
SellUS$55,19023 May 19
Charles Slacik
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,000
Max PriceUS$55.19
BuyUS$6,933,73221 May 19
Schuler Family Foundation, Endowment Arm
EntityCompany
Shares117,671
Max PriceUS$60.26
SellUS$1,013,86322 Feb 19
Mary Polan
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares14,449
Max PriceUS$70.17
SellUS$896,88520 Feb 19
Mary Polan
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares13,772
Max PriceUS$65.12
SellUS$922,65307 Dec 18
Randall Steward
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares15,000
Max PriceUS$61.51

Ownership Breakdown


Management Team

  • Randy Steward (65yo)

    Chief Financial Officer

    • Tenure: 7.9yrs
    • Compensation: US$1.37m
  • Doug Bryant (61yo)

    President

    • Tenure: 10.5yrs
    • Compensation: US$3.42m
  • Karen Gibson (57yo)

    Senior Vice President of Information Systems & Business Transformation

    • Tenure: 0yrs
  • Robert Bujarski (51yo)

    Senior VP of North America Commercial Operations & General Counsel

    • Tenure: 14.2yrs
    • Compensation: US$1.38m
  • Ratan Borkar (45yo)

    Senior Vice President of International Commercial Operations

    • Tenure: 1.9yrs
  • Werner Kroll (62yo)

    Senior Vice President of Research & Development

    • Tenure: 5.3yrs
    • Compensation: US$1.58m
  • Michael Abney (55yo)

    Senior Vice President of Distribution

    • Tenure: 4.7yrs
    • Compensation: US$1.49m
  • Ed Russell (51yo)

    Senior Vice President of Business Development

    • Tenure: 3.9yrs
    • Compensation: US$1.11m
  • Ruben Argueta

    Director of Investor Relations

    • Tenure: 0yrs
  • Phillip Askim

    Secretary

    • Tenure: 0yrs

Board Members

  • Ken Widder (66yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$161.85k
  • Ken Buechler (65yo)

    Chairman

    • Tenure: 4.1yrs
    • Compensation: US$226.34k
  • Doug Bryant (61yo)

    President

    • Tenure: 10.5yrs
    • Compensation: US$3.42m
  • Ed Michael (62yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$58.35k
  • Charlie Slacik (65yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$160.57k
  • Jack Schuler (79yo)

    Independent Director

    • Tenure: 13.6yrs
    • Compensation: US$152.13k
  • Mary Polan (75yo)

    Independent Director

    • Tenure: 26.6yrs
    • Compensation: US$152.13k
  • Kathy Ordoñez (68yo)

    Director

    • Tenure: 0.3yrs
  • Matthew Strobeck (46yo)

    Director

    • Tenure: 1.4yrs
    • Compensation: US$140.09k

Company Information

Quidel Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quidel Corporation
  • Ticker: QDEL
  • Exchange: NasdaqGS
  • Founded: 1979
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$2.660b
  • Shares outstanding: 41.44m
  • Website: https://www.quidel.com

Number of Employees


Location

  • Quidel Corporation
  • 12544 High Bluff Drive
  • Suite 200
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QDELNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 1983
QL1DB (Deutsche Boerse AG)YesCommon StockDEEUROct 1983
QBSWOTCBB (OTC Bulletin Board)YesCommon StockUSUSDOct 1983

Biography

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women’s and general health, eye health, gastrointestinal di ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:45
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.